Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668211 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL30028151 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29399598 | 0.91 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL30560164 | 0.90 | CASP3 (0.53) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29233233 | 0.90 | KMT2A (0.46) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL13295943 | 0.89 | KMT2A (0.54) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29697708 | 0.88 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29603695 | 0.88 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL8902890 | 0.88 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL27637562 | 0.88 | KMT2A (0.51) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023061405-A1 | HIGHLY-STABLE TARGETED LINKER-DRUG CONJUGATE | 成都科岭源医药技术有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | KMT2A 506/4885CASP3 2303/4885MDM4 3147/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | KMT2A 506/4885CASP3 2303/4885MDM4 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.